Ataxia telangiectasia mutant (ATM) is an S/T-Q-directed kinase that is critical for the cellular response to double-stranded breaks (DSBs) in DNA. Following DNA damage, ATM is activated and recruited by the MRN protein complex [meiotic recombination 11 (Mre11)/DNA repair protein Rad50/Nijmegen breakage syndrome 1 proteins] to sites of DNA damage where ATM phosphorylates multiple substrates to trigger cell-cycle arrest. In cancer cells, this regulation may be faulty, and cell division may proceed even in the presence of damaged DNA. We show here that the ribosomal s6 kinase (Rsk), often elevated in cancers, can suppress DSB-induced ATM activation in both Xenopus egg extracts and human tumor cell lines. In analyzing each step in ATM activation, we have found that Rsk targets loading of MRN complex components onto DNA at DSB sites. Rsk can phosphorylate the Mre11 protein directly at S676 both in vitro and in intact cells and thereby can inhibit the binding of Mre11 to DNA with DSBs. Accordingly, mutation of S676 to Ala can reverse inhibition of the response to DSBs by Rsk. Collectively, these data point to Mre11 as an important locus of Rsk-mediated checkpoint inhibition acting upstream of ATM activation.
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dsDNA IP | PMA | SL0101 | γ-H2AX C ells have evolved multiple pathways signaling DNA damage that trigger DNA repair, cell-cycle arrest and, in the event of irreparable damage, cell death. Among the various forms of DNA damage, double-stranded breaks (DSBs) in DNA, generated by exposure to ionizing radiation and radiomimetic chemicals such as neocarzinostatin (NCS), are the most lethal for cells (1) .
DSBs often are repaired by homologous recombination during the S and G2/M phases of the cell cycle, which involves the meiotic recombination 11 (Mre11)/DNA repair protein Rad50/ Nijmegen breakage syndrome 1 (Nbs1) (MRN) complex and the ataxia telangiectasia mutated (ATM) kinase (2, 3) . The MRN complex first recognizes sites of DNA damage and then promotes binding of ATM to the DSB site. ATM, activated by monomerization and autophosphorylation, phosphorylates downstream proteins including p53, checkpoint kinase 2 (Chk2), and breast cancer 1, early onset (BRCA1) (4-7). These factors then convey the signal to induce cycle arrest, apoptosis, or DNA repair (8) . Failure of this process results in genome instability, increasing the risk of cancer, neurodegeneration, and other pathologies (9) .
Ribosomal S6 kinase (Rsk), which functions downstream of mitogen-activated protein kinase kinase (MEK) and ERK, is frequently activated in cancer cells (10, 11) . Rsk activation can be promoted by multiple signaling pathways in cancer cells, including those triggered by steroids, insulin, EGF, and estrogen (10, (12) (13) (14) (15) . Additionally, Rsk activation can be triggered by PKC signaling [via the PKC/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinases (MAPK) pathway], which is activated by phorbol12-myristate13-acetate (PMA) (16, 17) . Previous studies have found that Rsk2 is overexpressed in 50% of breast cancers and prostate tumors (18, 19) , and Rsk signaling has been implicated in the regulation of survival, anchorage-independent growth, and transformation of breast cancer cells in culture (20) . Rsk-specific inhibition (with BI-D1870 or SL0101) significantly reduced proliferation of MCF7, PC3, or LnCaP cancer cells (18, 19) . Rsk also inhibits apoptosis in PC3 prostate cancer cells (21) .
A hallmark of cancer cells is their ability to override cell-cycle checkpoints, including the DSB checkpoint, which arrests the cell cycle to allow adequate time for damage repair. Previous studies have implicated the MAPK pathway in inhibition of DNA-damage signaling: PKC suppresses DSB-induced G2/M checkpoint signaling following ionizing radiation via activation of ERK1/2 (22) ; activation of RAF kinase, leading to activation of MEK/ ERK/Rsk, also can suppress G2/M checkpoint signaling (23) .
Given its prominent role in multiple cancers, the MAPK pathway is an attractive therapeutic target. Indeed, treatment of melanoma using the RAF inhibitor vemurafenib has shown some clinical success, as has treatment of nonsmall cell lung carcinoma with MEK inhibitors (24) . However, targeting components at the apex of a signaling pathway may induce side effects caused by the plethora of downstream effectors (25, 26) . As a terminal kinase in the MAPK pathway, Rsk may avoid these complications as a potential target. Thus, there has been interest in targeting Rsk for cancers with notable Rsk elevation (e.g., prostate cancers) (27) . Several Rsk-specific inhibitors have been described, including SL0101 and BI-D1870 (18, 28, 29) . Whether these or derivative drugs will be clinically successful remains unclear. However, if Rsk inhibition can reinstate DSB-induced checkpoint function, then combination therapy of Rsk inhibitors with DNA-damaging agents may be effective in inducing tumor cell arrest or death.
The precise mechanism underlying checkpoint inhibition downstream of MEK/ERK/Rsk signaling is not yet clear. One recent paper has shown that, after doxorubicin-induced DNA damage (both DSB and ssDNA breaks), Rsk can silence the G2/M checkpoint by phosphorylating (and inhibiting) the Chk1 kinase on S280 (the same site that can be targeted by protein kinase B/ Akt kinase) (30) . However, another group has reported that phosphorylation of this site on Chk1 enhanced its ability to enforce the checkpoint by promoting its nuclear translocation (31) .
We show here that Rsk signaling silences the DSB-induced G2/M checkpoint by preventing activation of the ATM kinase. Specifically, we have found that Rsk targets the Mre11 component of the MRN complex by phosphorylating S676, thereby preventing Mre11 binding to DNA. Mutation of S676 restored ATM activation, even in the face of high Rsk activity, and rendered
Significance
We have identified a pathway that links MAPK/ribosomal s6 kinase (Rsk) signaling to the inhibition of the response to a double-stranded break (DSB) in DNA, potentially explaining radioresistance in tumors with high rapidly accelerated fibrosarcoma (Raf)/MAPK/Rsk activity. The locus of this regulation was identified as meiotic recombination 11, whose phosphorylation by Rsk prevented its DNA binding and consequent activation of the central DSB checkpoint regulator, ataxia telangiectasia mutant. cells refractory to the checkpoint-inhibitory effects of Rsk. This finding is consistent with a previous study showing that phosphorylation on Mre11 is mostly inhibitory (32) . Taken together, these findings identify a locus of checkpoint regulation by Rsk and support the idea of targeting Rsk for therapeutic benefit.
Results
Prostate Cancer Cells with High Levels of Endogenous Rsk Are Resistant to DSBs. Rsk is highly expressed in many prostate cancer cell lines, including PC3 and LnCaP cells, which appear to be highly dependent on Rsk activity for growth and survival (19) . We hypothesized that Rsk might modulate the response of these cells to DNA damage-induced checkpoint function. To evaluate this hypothesis, we analyzed cell-cycle progression after DSB induction in PC3 cells that endogenously express twice the level of Rsk protein found in normal prostate tissue (19) . Cells were arrested at G1/S using double thymidine block and 4 h after release were treated with PMA and/or SL0101, followed by NCS to induce DSBs during the G2 phase. After drugs were washed away, cells were incubated in fresh media for 16 h before DNA contents were analyzed. As shown in Fig. 1A , cotreatment of cells with SL0101 and NCS resulted in much more robust G2/M arrest than seen with NCS alone. Additionally, after PMA-induced Rsk activation, the DSB-induced G2/M arrest was effectively overridden. We obtained similar results in experiments in which Rsk1/2 were knocked down using siRNA (Fig S1A) . Taken together, these data suggest that Rsk might inhibit the DSB checkpoint in PC3 prostate cancer cells. To examine this possibility further, we stained PC3 cells for γ-H2AX, a downstream target of ATM. As shown in Fig.  1B , PC3 cells treated with SL0101 before NCS treatment displayed greatly increased γH2AX staining. These data strongly suggest that high Rsk activity can suppress ATM-dependent G2/M checkpoint signaling.
Although it has been reported that inhibiting ATM may enhance G2/M accumulation (33) , inhibiting ATM decreased the G2/M population in the cell lines we used (Fig S1B) . This result also is consistent with other published studies (34, 35) .
To determine if Rsk is sufficient to confer resistance to DSBinduced G2/M arrest, we overexpressed constitutively active Rsk2 in 293T cells, which have much lower endogenous levels of Rsk than PC3 cells. As shown in Fig. 1C , Rsk-expressing cells were considerably less sensitive to DNA damage than control cells. To demonstrate G2/M checkpoint suppression, directly, we synchronized HeLa cells in G1/S phase by double thymidine block and treated them 4 h after release with PMA or SL0101 for 30 min and with NCS for an additional 30 min. Three or five hours later, cells were stained with anti-phospho-Histone H3 (PHH3) antibody. As shown in Fig. S1C , NCS significantly reduced the number of pHH3-positive cells by arresting cells in G2 phase. However, PMA treatment greatly increased the pHH3-positive population (particularly at 5 h), suggesting that the G2/M checkpoint had been silenced. This checkpoint inhibition was reversed by cotreatment with SL0101, confirming a role for Rsk in this silencing. Rsk Suppresses the DSB Response by Inhibiting the Activation of ATM.
To identify the locus of Rsk action within the DSB-signaling pathway, we assessed the status of the ATM kinase following NCS treatment in cells overexpressing constitutively active Rsk2. We found that after treatment with NCS these cells had reduced ATM phosphorylation at S1981 (a hallmark of ATM activation) but no change in ATM protein levels ( Fig. 2A) . Similarly, PMA treatment markedly decreased ATM autophosphorylation at S1981. However, ATM phosphorylation was restored when cells were treated with both PMA and SL0101 (Fig. S2A) . To demonstrate further the down-regulation of ATM, we measured phosphorylation of NBS1 at S343, a site known to be targeted by ATM. As expected, phosphorylation of NBS1 was reduced in the presence of PMA, consistent with Rsk-mediated reduction in ATM activity (Fig. S2B) . Accordingly, siRNA knock down of Rsk in PC3 cells significantly increased ATM autophosphorylation in response to NCS treatment (Fig. 2B) . ATM autophosphorylation is a very early event in the DSB response, and these data suggest that Rsk acts either at or upstream of ATM. As is consistent with an effect of Rsk signaling on ATM activity, HeLa cells treated with PMA stained more weakly with antibody directed against γH2AX than did untreated cells, and cotreatment with PMA and SL0101 reversed the diminution in γH2AX staining ( Fig. 2C and Fig. S2C ). HeLa cells transfected with FLAG-tagged constitutively activated Rsk2 exhibited significantly less γH2AX staining than nontransfected cells after NCS treatment ( Fig. 2D and Fig.  S2D ). This effect was reversed by treatment with SL0101 ( Fig. 2D and Fig. S2D ). Collectively, these data suggest that Rsk signaling suppresses both ATM activation and phosphorylation of its downstream targets, NBS1 and H2AX. It is worth noting that ATM activation is detected robustly only at the early phases of the DSB response (and thus the effects of Rsk could not be detected later, at 24 h) (Fig. S2E ). This situation probably reflects checkpoint adaptation or recovery from DNA damage, as is consistent with previous reports (36, 37) . However, cells were still phenotypically arrested at 24 h because either (i) the remaining ATM activity/DSB response is sufficient to maintain the checkpoint or (ii) checkpoint recovery lags behind DSB response recovery because cells require time to resume the cell cycle even though the upstream DNA-damage signals have waned.
The Moloney Sarcoma Oncogene/MAPK/Rsk Pathway Inhibits Binding of the MRN Complex to dsDNA. To identify the direct targets of Rsk responsible for inhibiting the DSB response, we used the Xenopus egg extract system, in which DSB checkpoint signaling can be reconstituted in vitro. This system allows easy manipulation of both DNA templates and Rsk signal components. Interphase extracts prepared from Xenopus eggs (crude S extracts) were treated with recombinant maltose-binding protein (MBP)-tagged Moloney sarcoma oncogene (Mos) kinase, a strong upstream activator of the MAPK pathway, leading to robust Rsk activation (38) . This treatment markedly inhibited autophosphorylation of ATM induced by dsDNA without altering ATM levels. SL0101 treatment reversed this inhibition (Fig. 3A) . To rule out the possibility that signaling by other Mos-activated kinases might cause the inhibition of the DSB response, we treated crude S extracts with prephosphorylated constitutively activated Rsk, and observed a similar decrease in ATM autophosphorylation (Fig.  3B ). Because ATM must be recruited to the site of DNA break by the MRN complexes before autophosphorylation and monomerization, we investigated the binding of ATM to dsDNA. We immobilized biotin-tagged dsDNA on avidin beads to mimic sites of dsDNA damage, incubated the beads with crude S extracts, and retrieved DNA bead-associated proteins. We observed a significant decrease in dsDNA-bound ATM after pretreatment of extracts with Mos, whereas binding of another DNA damageresponse protein, Ku70, was unchanged (Fig. 3C ). To rule out the possibility that decreased ATM binding resulted from reduced ATM activity, we supplemented extracts with the ATM/ ataxia telangiectasia and Rad3-related protein (ATR) kinase inhibitor caffeine; this supplementation did not reverse the decrease in ATM/DNA binding (Fig. 3D) . Together, these data suggest that Rsk functions upstream of ATM, affecting its recruitment to sites of DNA damage.
Because ATM recruitment is preceded by recognition of DNAdamage sites by the MRN complex, we investigated whether the binding of the MRN complex to dsDNA is affected by Rsk. Indeed, less Mre11 protein was associated with dsDNA in the crude S extracts pretreated with Mos than with control MBP protein. Moreover, SL0101 suppressed the effect of Mos (Fig. 3D) . The association of Mre11 with the beads was DNA dependent; an excess of free DNA significantly decreased the levels of beadbound Mre11 (Fig. S3A) . Moreover, treatment with either the ATM inhibitor KU55933 or ATM/ATR inhibitor caffeine did not reverse Rsk's inhibition of Mre11 binding. This result strengthens the suggestion that the observed effect on MRN complex/DSB DNA assembly was not caused by feedback from downstream ATM signaling ( Fig. 3D and Fig. S3A ). To confirm these findings in intact cells, we stained HeLa cells with anti-Mre11 antibody. PMA activation of Rsk significantly reduced the formation of Mre11/MRN foci, suggesting that Rsk indeed was suppressing the binding of the MRN complex to the DSB DNA (Fig. S3B ).
To rule out the possibility that Rsk disrupts the interaction between Mre11 and other MRN complex components, we investigated binding of Mre11 to Nijmegen breakage syndrome 1 proteins (Nbs1) in egg extracts without added DNA. We did not observe any effect of Rsk on the phys-ical interaction between these two proteins (Fig. S3C) , supporting the hypothesis that Rsk interferes with Mre11 binding to DNA but not with the formation of the MRN complex itself. To confirm that Rsk mediates suppression of ATM activation through the MRN complex, we treated cells with H 2 O 2 , which activates ATM independently of the MRN complex (39) . Cells overexpressing Rsk displayed no change in ATM activation following H 2 O 2 treatment, in agreement with our conclusion that Rsk silences ATM activation through suppression of MRN complex binding to DNA (Fig. S3D ).
S676 on Mre11 is the Target of Rsk. To identify specific target(s) of Rsk, we isolated DNA-bound proteins from crude S egg extracts and incubated the precipitates with Rsk and radiolabeled ATP. The one major protein band identified by SDS/PAGE and autoradiography was ∼85 kDa, which is the molecular weight of Mre11, suggesting that Mre11 might be a direct target of Rsk (Fig. S4A ). This result was confirmed using His-tagged recombinant Mre11, which could be directly phosphorylated by Rsk2 kinase (Fig. 4A) . To determine if the decreased MRN/ dsDNA binding was cause by phosphorylation of Mre11, we prephosphorylated Mre11 with Rsk2 and then incubated Mre11 with crude S extracts for 15 min (to allow association of other required factors) before precipitating the dsDNA. As shown in Fig. 4B , prephosphorylation by Rsk2 reduced the binding of Mre11 to dsDNA, suggesting that phosphorylation of Mre11 contributes to Rsk-mediated inhibition of the DSB response. To identify the relevant sites of phosphorylation on Mre11, we phosphorylated recombinant His-tagged Mre11 with Rsk in vitro and analyzed the protein by mass spectrometry. We identified four phosphorylated residues: 2, 641, 676, and 688. Although none of those four sites was identical to the Rsk consensus site RXRXXpS/T, Rsk can target nonoptimal sites (40) . We mutated each of the identified sites and performed in vitro Rsk assays using the recombinant mutants. Although several of the sites reduced phosphorylation, the single S676A mutation abolished phosphorylation almost completely, suggesting that S676 is the major site of in vitro phosphorylation by Rsk (Fig. 4C ). Mre11 phosphorylation also was severely compromised by mutation of S676 when radiolabeled ATP was added to lysates that had been prepared from cells transfected with Rsk (Fig. S4B) . Note that in this experiment, cells were not serum starved before lysate production, and thus WT or constitutively activated Rsk proteins behaved similarly (because of the activation of the transfected WT Rsk). As is consistent with our in vitro data, we successfully detected endogenous Mre11 S676 phosphorylation in the presence of PMA or overexpressed WT/constitutively active Rsk with an antibody that targeted phospho-S676 (Fig. 4 D and E) . Phosphorylation induced by PMA was abrogated by cotreatment with the Rsk inhibitor SL0101 (Fig. 4 D and E) . In addition, we treated Rsk-transfected cells with a DNA PK inhibitor to rule out the possibility that Rsk might cause Mre11 S676 phosphorylation indirectly by activating DNA PK (Fig. S5A) . Although the DNA PK inhibitor was effective against a known DNA PK substrate, Akt, it did not inhibit phosphorylation of Mre11 downstream of Rsk (Fig.  S5B) . Collectively, these data suggested that Rsk can phosphorylate S676 of Mre11 both in vitro and in intact cells.
Phosphorylation of Mre11 on S676 Reduces Its Binding to dsDNA and Is Responsible for Checkpoint Inhibition by Rsk. Mre11 has two potential DBDs, and S676 is located within the second of these ( Fig.  5A) (41, 42) . Therefore, we speculate that phosphorylation of Mre11 on S676 might directly disrupt its binding to dsDNA. As shown in Fig. 5B , Mos treatment of egg extracts reduced binding of WT Mre11 to DNA beads but had no effect on the S676A mutant. Moreover, pretreating recombinant WT Mre11 with Rsk reduced the amount of DNA-bound Mre11, but this effect was not seen when the S676A mutant was used (Fig. 5C ). Consistent with the role for Mre11 S676 phosphorylation in the control of ATM by Rsk, we found that the ability of Mos to inhibit DSB-induced ATM activation in Xenopus egg extracts was dampened significantly by the addition of the S676A mutant Mre11 (Fig.  5D) . Moreover, upon expression in 293T cells, the S676A mutant conferred resistance to Rsk-mediated G2/M checkpoint inhibition, whereas the control mutant (mutated at the other sites originally seen by mass spectrometry, 2A/641A/688A) did not (Fig. 5E) . We further investigated whether Rsk directly inhibited the formation of Mre11/MRN foci in Mre11-mutant cells. We knocked down endogenous Mre11 in HeLa cells using shRNA and transfected cells with shRNA resistant WT Mre11 or S676A. PMA treatment reduced the Mre11 foci in cells expressing WT Mre11 but not in the cells expressing the S676A mutant ( Fig. 5F and Fig. S6 ). Moreover, SL0101 reversed the effect of PMA in the WT-expressing cells, as is consistent with a role of Rsk in controlling the formation of Mre11/ MRN foci via phosphorylation of Mre11 S676 (Fig. 5F and Fig. S6 ).
Discussion
We have shown here that Rsk signaling impairs cell-cycle arrest by the DSB-induced G2/M checkpoint by inhibiting the ATM pathway. This effect appears to involve a failure to activate ATM through MRN-mediated recruitment to sites of DNA damage. We found that Mre11 protein, a core constituent of the MRN complex, was phosphorylated by Rsk both in vitro and in intact cells. Furthermore, through mutagenesis experiments, one of the identified phosphorylation sites, S676, was demonstrated to be essential for functionally inhibiting Mre11. Together, these findings provide a mechanism for Rsk-induced inhibition of DSB checkpoint function.
A recent paper investigating the role of Rsk in G2/M arrest following doxorubicin treatment reported that Rsk could phosphorylate Chk1 at S280, the site that is targeted by Akt kinase to inhibit Chk1 activity (30) . However, a similar study showed that the same phosphorylation on Chk1 had the opposite effect (31).
Our findings are distinct from these reports in demonstrating that Rsk-mediated inhibition of ATM activation can be achieved by targeting steps upstream of ATM activation. In addition, Rsk can suppress G2/M checkpoint function following DSB in cells knocked down for Chk1, suggesting that Rsk phosphorylation of Mre11 contributes to DSB-induced G2 checkpoint silencing independently of Chk1 (Fig. S7A) .
The finding that phosphorylation on Mre11 at S676 inhibited its binding to the DSB also is consistent with a previous report demonstrating that mutation of eight SQ/TQ sites on Mre11, including S676, undermined the negative feedback loop whereby ATM terminates the checkpoint response by inhibiting DNA binding by Mre11 (32) . Our study strongly suggests that S676 is, at least in part, responsible for such inhibition and that S676 phosphorylation can prevent binding of Mre11 to dsDNA not only in Xenopus extracts but also in mammalian cells. In addition, we implicate Mre11 phosphorylation as a factor in a critical checkpoint inhibitory pathway that results from high ambient MAPK signaling in cancer cells. Interestingly, Di Virgilio et al. suggested that ATM is not the only kinase responsible for the phosphorylation of the observed eight SQ/TQ phospho-sites (32). Indeed, it is possible that Rsk not only participates in a checkpoint inhibitory pathway but also acts downstream of ATM in the pathway of feedback inhibition. In other words, it may be that ATM can inhibit Mre11 by activating Rsk. We note that the converse cannot be true-i.e., Rsk cannot activate ATM to phosphorylate Mre11-because ATM inhibition did not preclude Rsk-mediated phosphorylation or inhibition of Mre11.
The DNA-damage response and its regulation have been shown to play a critical role in tumorigenesis; the DSB-response pathway can be turned off early in tumor development in multiple types of cancer. This abrogation of checkpoint function prevents cellcycle arrest, leads to error-prone DNA replication, and promotes accumulation of multiple cellular mutations (which can fuel cancer progression) (43, 44) . Moreover, because the primary goal of radiation therapy is the generation of abundant DSBs to induce permanent cell-cycle arrest and/or apoptosis, the overriding of DSB-induced checkpoint function can undermine the utility of this treatment modality. Indeed as shown in Fig. S7B , in the cells we tested, up-regulation of Rsk rendered cells resistant to excessive DSB-induced cell death. However, it should be noted that in some radioresistant tumors the DSB response and DNA repair are upregulated rather than inactivated, leading to efficient repair of radiation-induced DNA damage (45) . Consequently, the therapeutic benefit of inhibiting or activating the DSB response is likely to vary depending on tumor type. This variance has clear implications for Rsk as a target of tumor therapy. In cancer cells that inhibit their checkpoint function through Rsk, Rsk inhibition might be synergistic with ionizing radiation. The consequences of inhibiting Rsk for cancer therapy extend beyond the impact on cell-cycle checkpoints and DNA repair. Recently, our laboratory reported that Rsk can phosphorylate the apoptotic inducer Apaf-1 and thereby reduce its apoptotic activity (21) . Similarly, it has been reported that Rsk can inhibit the action of Bax/Bad complexes, a pivotal mediator of cell death following both chemotherapy and radiation (46) . Therefore, at least for tumors with high Rsk activity, inhibition of Rsk may restore DNA damage-induced cell-cycle arrest while at the same time removing the brake on apoptosis. In these tumors, Rsk inhibitors may extend the utility of both irradiation and DNAdamaging chemotherapeutics.
Materials and Methods
Detailed information on materials and protocols is given in SI Materials and Methods.
Xenopus Extracts and DNA Immunoprecipitation. Cytostatic factor (CSF) extracts and interphase extracts were prepared as previously described (38) . Detailed information is provided in SI Materials and Methods.
Immunostaining. HeLa cells were grown on coverslips, were treated with different drugs as described in Results, and were fixed with 4% (vol/vol) paraformaldehyde for 20 min. Immunostaining was performed as described previously (47) using anti-γH2AX antibody.
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Chen et al. 10 .1073/pnas.1306328110 SI Materials and Methods Xenopus Extracts and DNA Immunoprecipitation. For extracts treated with DSB DNA, 5 μL of 0.01 mM dAdT dsDNA (70 nt) was added to 50-μL extracts. Extracts were incubated at room temperature. For DNA precipitations, 1 μL of biotin-tagged dsDNA (0.25 mM) was bound to 25 μL of avidin beads for each reaction. DNA-bound beads then were incubated with 100-μL extracts for 20 min at room temperature. Beads were removed from extracts and washed four times with egg lysis buffer (250 mM sucrose, 2.5 mM MgCl, 1 mM DTT, 50 mM KCl, and 10 mM Hepes, pH 7.7).
Cell Culture and Drug Treatments. 293T, HeLa, or MCF7 cells were maintained in high-glucose DMEM medium supplemented with 10% FBS. PC3 cells were maintained in F12K medium. Cells were grown to 90% confluence before treatment with drugs. For SL0101 treatment, 1 μL of 100 mM SL0101 was added to 1 mL of medium for a final concentration of 100 uM. Cells were treated with SL0101 for 30 min. For phorbol12-myristate13-acetate (PMA) treatment, 0.5 μL of PMA (50 ng/μL) was added to 1 mL of medium to make final a concentration of 25 ng/mL Cells were treated for 30 min. For neocarzinostatin (NCS) treatment, 0.2 μL of NCS (500 ng/mL) was added to 1 mL medium to make a final concentration of 200 ng/mL After treatment for 30 min, cells were washed once with PBS.
Transfection and siRNA. FuGENE 6 (Roche) was used to transfect cells with plasmids according to the manufacturer's instructions. Lipofectamine RNAiMAX (Invitrogen) was used to perform siRNA transfections. siRNA targeted against ribosomal s6 kinase 1 (RSK1) and RSK2 as previously described (40) were purchased from Sigma.
Plasmid Reagents and Antibodies. C-terminal HA-tagged meiotic recombination 11 (Mre11) and N-terminal Flag-tagged RSK2 were cloned into pCDNA3 plasmid. Mre11 alanine mutants and the constitutively active RSK2 707A mutant were generated by site-directed mutagenesis. The antibodies against human Mre11 (Abcam), phospho-S6 Ser235/236 (Cell Signaling), phosphorhistone H3 (Ser10) (Cell Signaling), actin (Santa Cruz), phosphor-Mre11 Ser-676 (Cell Signaling), goat anti-HA (Abcam), His-probe (Santa Cruz), γH2AX Ser139 (Cell Signaling), human ataxia telangiectasia mutant (ATM) (Abcam), phospho-ATM Ser1981 (Epitomics), and anti-human/Xenopus Mre11 (Calbiochem) were obtained as stated.
The antibodies against Xenopus Nijmegen breakage syndrome 1 (Nbs1) and ATM were gifts from William Dunphy (California Institute of Technology, Pasadena, CA).
The following drugs were used: PMA (Enzo Life Science), NCS (Sigma), SL0101 (Calbiochem), and Ku55933 (Calbiochem).
Biotin-tagged ssDNA was purchased from Integrated DNA Technologies. Biotin-tagged dsDNA was synthesized by annealing tagged ssDNA with its anti-sense DNA at 70°C and gradual cooling to room temperature.
Kinase Assay. For kinase assays in mammalian cell lysates, nickelagarose-bound Mre11-His was incubated with 2 μCi γ-[
32 P]ATP in cytosolic lysates from mammalian cells transfected with RSK2 for 1 h at 30°C. Beads then were removed and washed three times in washing buffer [1 mM Hepes-KOH (pH 7.5), 1 mM β-glycerophosphate, 15 mM KCl, 0.1% Nonidet P-40, 14.8 mM imidazole, 500 mM NaCl, 1 mM NaVO 3 , and 5 μg/mL aprotinin/ leupeptin].
For the in vitro kinase assay, nickel-agarose-bound Mre11-His protein was incubated in kinase buffer [10 mM Tris·HCl (pH 7.5), 0.1 mM ATP, 10 mM MgCl 2 , 1 mM DTT (pH 7.2)] with 2 μCiγ-[
32 P]ATP and RSK2 kinase (Millipore). After 30 min at 30°C, the beads were washed with washing buffer. Analysis for all kinase assays was performed using SDS/PAGE and autoradiography.
Immunoblot Analysis. For tissue culture, cells were cultured to 90% confluence before harvesting with trypsin. Cells then were lysed with extraction buffer [20 mM Hepes (pH 7.4), 150 mM NaCl, 12.5 mM M glycerophosphate, 1.5 mM MgCl 2 , 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na 3 VO 4 , 20 μM aprotinin, 1 mM PMSF, and 0.5% Triton X-100]. The concentration of cell lysates was measured. Equal amounts of lysates were loaded for SDS/PAGE. Proteins were transferred from gels to PVDF membrane and were immunoblotted with antibodies. For large-molecular-weight proteins such as ATM, low-voltage (50 V) was used in the overnight transfer.
For Xenopus extracts, 5 μL of extract was mixed with 50 μL SDS sample buffer. Extracts and samples were loaded for SDS/ PAGE, transferred from gels to PVDF membrane, and processed for immunoblotting with antibodies. 
